3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study

Summary

A dose defining study of the protease inhibitor tipranavir (TPV), boosted with low dose ritonavir (RTV). Three dose combinations of TPV/RTV are administered to multiple antiretroviral experienced patients and the dose that achieves the best efficacy and safety as determined by evaluation of 2, 8, and 24-week virologic response and adverse event and laboratory profile measures would be selected for further clinical study.

Timeline

Start

2002-03-29

Primary completion

2003-01-20

Completion

—

Drugs

Indications